Reviewed by Adam Gardner, Licensed Pharmacist & COO of TelyRx
If you’re one of the millions of Americans living with a liver condition, there’s some exciting news on the horizon.
In August 2025, the FDA approved Wegovy®, the breakthrough GLP-1 medication that’s made headlines for its value in weight loss, to treat MASH (Metabolic dysfunction-associated steatohepatitis), an advanced form of fatty liver disease.
This expanded approval could be life-changing news for people who didn’t even know they were at risk, because MASH is one of those silent health threats that can quietly damage your liver for years. According to Stanford Health Care, by the time symptoms like fatigue or abdominal discomfort appear, the disease has often progressed beyond its early stages, and significant liver damage may have already occurred.
To appreciate why this new FDA approval matters so much, it’s helpful to know that MASH is actually part of a metabolic disorder that falls along a spectrum. At one end, you have early-stage fatty liver, which happens when fat accumulates in your liver cells but doesn’t cause significant inflammation.
At the other end, you have full-blown MASH, where that accumulated fat triggers serious inflammation and your liver comes under active attack. It’s estimated that roughly a quarter of people worldwide have some form of fatty liver disease, but the truly alarming part? Most don’t even know it.
Think of it this way: if early-stage fatty liver is like having a buildup of clutter in your home – inefficient and annoying but something you can live with – MASH is like having that clutter catch fire. The fat is no longer just sitting there taking up space; it’s causing real damage.
Read on to learn more about MASH and how this new treatment option is blazing a more promising path forward.
Now that you see how this progression works, let’s dispel a dangerous myth that can delay both diagnosis and treatment: “Only overweight people develop MASH.” According to a 2022 article published in the peer-reviewed journal Diabetology & Metabolic Syndrome, MASH affects as many as one in three people of healthy weight. This misconception can lead both patients and doctors to rule out the disease entirely when someone appears to be in good shape.
Without dietary and lifestyle changes, fatty liver can develop into MASH. And when left untreated, MASH can progress to cirrhosis, severe scarring that permanently impairs liver function. In some cases, it can even lead to liver cancer.
It’s important to understand that your risk of developing MASH is correlated with your internal metabolic health, not necessarily with your outer appearance. Key risk factors include:
- High visceral fat: This is the dangerous fat that surrounds your internal organs and can be both metabolically active and inflammatory.
- Insulin resistance: This often exists long before blood sugar levels become obviously abnormal.
- High triglycerides, high cholesterol, and high blood pressure.
The point is, your risk for MASH depends on your metabolic health, not the number on your scale.
This approval matters because it gives people with MASH another proven option that can effectively help reverse the progression of the disease. The clinical trial results from The ESSENCE phase 3 trial were impressive.
So, what did the trials actually show?
- 63% of people treated with Wegovy® achieved resolution of steatohepatitis and no worsening of liver fibrosis compared to 34% on placebo—a statistically significant difference of 29%.
- 37% of people treated with Wegovy® achieved improvement in liver fibrosis and no worsening of steatohepatitis compared to 22% on placebo—a significant 15% improvement over placebo.
Translation: Nearly two-thirds of patients saw MASH resolution with significant improvements in liver scarring. This represents a major breakthrough in treating a condition that, until recently, had very few treatment options.
This is a key finding because it shows that Wegovy® isn’t just treating symptoms; it’s actively helping to reverse the progression of the disease.
The journey to diagnose and treat MASH often begins at a routine checkup. Your doctor might notice a red flag, like elevated liver enzymes on blood work, or they might see something suspicious on an ultrasound, such as a “bright” or fatty-looking liver.
These initial screenings are important clues, but they don’t provide the whole picture. To get a definitive diagnosis and confirm how advanced the condition is, doctors may recommend a liver biopsy. Biopsies can be invasive and expensive, but they’re still considered the gold standard, especially when other tests are inconclusive.
Getting a MASH diagnosis is the first step. Accessing effective treatment presents a whole new set of challenges. Some find it hard to track down a doctor who is up to date on the latest MASH treatment options. Others hit a wall with their insurance, as many plans require prior authorization or extensive documentation before they’ll cover newer medications like Wegovy®.
Even after you get a prescription, the journey to resolution is far from over: Drug and stock shortages for popular GLP-1 medications are incredibly common. The complex insurance process can also cause weeks of delays while you wait for prior authorizations to go through.
On top of that, pharmacy staff often end up on the front lines, dealing with the administrative burden of insurance approvals and coverage checks, resulting in pharmacy pushback when what you’re looking for are green lights. All of these obstacles lead to the same frustrating result: delays in getting the medication you need.
Fortunately, these traditional healthcare barriers do not have to be the end of the story. We believe that getting access to essential medications should be straightforward, convenient, and available to everyone who needs them.
That’s why TelyRx exists. TelyRx connects you with independent, licensed physicians who are informed on the latest treatment options and can evaluate whether a medication like Wegovy is clinically appropriate for your situation. Unlike many retail pharmacies, TelyRx’s licensed pharmacies source medications from a variety of reputable U.S. wholesalers, helping ensure more consistent availability of medications like Wegovy.
Beyond using platforms like TelyRx for faster prescriptions and medication access, there are plenty of simple and natural ways to support your liver and overall metabolic health. Whether you’re at risk for MASH or managing an existing diagnosis, these evidence-based approaches can make a meaningful difference:
This blog post is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content provided here is not a substitute for professional medical advice, consultation, or care from a qualified healthcare provider. Always seek the guidance of your physician or another licensed health professional with any questions you may have regarding a medical condition or treatment. Do not disregard or delay seeking professional medical advice based on information read on this site. Learn more about our editorial standards.